[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Gasparetto EL, Cruz Jr LC, Doring TM, Araújo B, Dantas MA, Chimelli L, Domingues RC: Diffusion-weighted MR images and pineoblastoma: diagnosis and follow-up. Arq Neuropsiquiatr; 2008 Mar;66(1):64-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted MR images and pineoblastoma: diagnosis and follow-up.
  • Pineoblastomas are uncommon pineal tumors, which demonstrate rapid growing and poor prognosis.
  • We report the case of a 43-year-old man with an enhancing pineal region mass, which showed restriction of the diffusion on diffusion-weighted (DW) MR images.
  • The surgical biopsy defined the diagnosis of pineoblastoma and the therapy was initiated with radiation and chemotherapy.
  • The differential diagnosis of pineal region masses that could show restriction of diffusion is discussed.
  • [MeSH-major] Brain Neoplasms / diagnosis. Pineal Gland. Pinealoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Diffusion Magnetic Resonance Imaging. Follow-Up Studies. Humans. Male

  • Genetic Alliance. consumer health - Pineoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392417.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


2. Gill P, Litzow M, Buckner J, Arndt C, Moynihan T, Christianson T, Ansell S, Galanis E: High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system. Cancer; 2008 Apr 15;112(8):1805-11
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
  • BACKGROUND: Embryonal central nervous system (CNS) tumors (medulloblastoma, cerebral neuroblastoma, pineoblastoma, and primitive neuroectodermal tumors) are rare in adults.
  • The use of high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) has demonstrated promising results in children with recurrent disease, but there are only limited data regarding its role in adults.
  • The purpose of the current study was to evaluate adult patients with embryonal CNS tumors who were treated with HDC with ASCT and compare their outcomes with those of patients who received conventional-dose chemotherapy.
  • The authors compared treatment with HDC with ASCT (10 patients) with an historic control of patients treated with conventional-dose chemotherapy (nitrosourea based, cisplatin based, or both) (13 patients).
  • RESULTS: HDC with ASCT was associated with increased survival (P= .044) and a longer time to disease progression (TTP) (P= .028).
  • The conventional-dose chemotherapy group had a median TTP of 0.58 years and a median survival of 2.00 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Medulloblastoma / drug therapy. Neoadjuvant Therapy. Neoplasm Recurrence, Local / drug therapy. Stem Cell Transplantation / methods

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer. 2008 Apr 15;112(8):1643-5 [18306390.001]
  • (PMID = 18300237.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 35S93Y190K / Procarbazine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 905Z5W3GKH / Thiotepa; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


3. Shih CS, Hale GA, Gronewold L, Tong X, Laningham FH, Gilger EA, Srivastava DK, Kun LE, Gajjar A, Fouladi M: High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors. Cancer; 2008 Mar 15;112(6):1345-53
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors.
  • BACKGROUND: High-dose chemotherapy (HDCT) with autologous stem cell rescue (ASCR) has been reported to be effective in treating children with recurrent central nervous system (CNS) malignancies.
  • METHODS: To evaluate the efficacy and toxicities of HDCT and ASCR, the medical records of 27 children with recurrent CNS malignancies who received such therapy at St. Jude Children's Research Hospital between 1989 and 2004 were reviewed.
  • RESULTS: The median age at diagnosis was 4.5 years (range, 0.4-16.6 years) and that at ASCR was 6.7 years (range, 1.1-18.5 years).
  • Diagnoses included medulloblastoma (13 patients), primitive neuroectodermal tumor (3 patients), pineoblastoma (2 patients), atypical teratoid rhabdoid tumor (2 patients), ependymoma (3 patients), anaplastic astrocytoma (2 patients), and glioblastoma multiforme (2 patients).
  • The 5-year PFS rate for patients aged<3 years at diagnosis (57.1%) was significantly better than older patients (5.0%) (P=.019).
  • Among the 6 long-term survivors (5 with M0 disease and 1 with M3 disease at diagnosis), 5 received both radiotherapy and HDCT as part of their salvage regimen; 4 were aged<3 years at diagnosis and had received chemotherapy only as part of frontline therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Ependymoma / diagnosis. Ependymoma / therapy. Female. Follow-Up Studies. Glioblastoma / diagnosis. Humans. Infant. Male. Medulloblastoma / pathology. Medulloblastoma / therapy. Neuroectodermal Tumors, Primitive / diagnosis. Neuroectodermal Tumors, Primitive / therapy. Pinealoma / pathology. Pinealoma / therapy. Retrospective Studies. Rhabdoid Tumor / pathology. Rhabdoid Tumor / therapy. Salvage Therapy. Survival Rate. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 18224664.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA023944; United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Barlas O, Bayindir C, Imer M, Ayan I, Darendeliler E: Non-resective management of pineoblastoma. Minim Invasive Neurosurg; 2000 Sep;43(3):163-70
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-resective management of pineoblastoma.
  • The results of a non-resective treatment approach for pineoblastoma comprising stereotactic biopsy, cerebrospinal fluid diversion, and fractionated radiotherapy in six patients over a period of six years are presented.
  • There were three male and three female patients, with a median age at diagnosis of 20 years.
  • Recurrences were treated with interstitial irradiation with iodine-125 seeds in four instances, repeat radiotherapy when time elapsed was more than five years in one instance, with surgical resection in two instances, and chemotherapy in two instances.
  • The diagnostic and therapeutic effectiveness of this management strategy is assessed.
  • The median follow-up time was 48 months (range 14-70 months).
  • One patient died of disease at 28 months following diagnosis.
  • The results of this study suggest that this non-resective treatment approach is acceptable as an initial treatment alternative to radical surgical resection of pineoblastomas.
  • [MeSH-major] Brain Neoplasms / therapy. Pineal Gland. Pinealoma / therapy
  • [MeSH-minor] Adolescent. Adult. Biopsy. Cerebrospinal Fluid Shunts. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local. Tomography, X-Ray Computed. Treatment Outcome. Ventriculostomy

  • Genetic Alliance. consumer health - Pineoblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11108118.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  •  go-up   go-down


5. Gilheeney SW, Saad A, Chi S, Turner C, Ullrich NJ, Goumnerova L, Scott RM, Marcus K, Lehman L, De Girolami U, Kieran MW: Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy. J Neurooncol; 2008 Aug;89(1):89-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy.
  • INTRODUCTION: Pineoblastomas are a category of supratentorial primitive neuroectodermal tumors (sPNETs) occurring in the pineal gland; some studies support the impression that patients with pineoblastomas have a worse prognosis than those with other sPNETs.
  • METHODS: We reviewed the medical records and tissue sections of all patients with the diagnosis of pineoblastoma that were treated at the Dana-Farber Cancer Institute/Children's Hospital Boston Pediatric Brain Tumor Program between 1986 and 2005.
  • RESULTS: Thirteen patients with the pathologic diagnosis of pineoblastoma were treated at our Hospital; 11 of these cases had complete records suitable for study.
  • Patients who received CSI and multi-agent chemotherapy had improved overall survival.
  • CONCLUSIONS: Seven of eleven patients with pineoblastoma are currently alive and free of disease, reflecting an improved outcome and longer survival than previously appreciated.
  • Gross total surgical resection appeared to correlate with improved survival, as did treatment with craniospinal irradiation and multi-agent chemotherapy.
  • Further study of this group of patients as a distinct diagnostic entity will be necessary to determine optimal therapy.
  • [MeSH-major] Pineal Gland / pathology. Pinealoma
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Drug Therapy / statistics & numerical data. Female. Humans. Infant. Male. Neurosurgical Procedures / standards. Neurosurgical Procedures / statistics & numerical data. Prognosis. Radiotherapy / statistics & numerical data. Retrospective Studies. Secondary Prevention. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pineoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 2006 Jun;22(6):577-85 [16555075.001]
  • [Cites] Childs Nerv Syst. 1999 Oct;15(10):586-91 [10550590.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):959-67 [9869216.001]
  • [Cites] Acta Neuropathol. 2006 Jul;112(1):5-12 [16685513.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1687-96 [7602359.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1377-83 [7751882.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10 (16):5482-93 [15328187.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):994-8 [14970184.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):552-60 [11900240.001]
  • [Cites] Neurol Clin. 2003 Nov;21(4):897-913 [14743655.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1814-23 [9164190.001]
  • [Cites] Neurosurg Focus. 2005 Nov 15;19(5):E3 [16398467.001]
  • [Cites] Med Pediatr Oncol. 2002 Sep;39(3):168-74 [12210445.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):644-50 [15105654.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Oct 15;170(2):175-9 [17011992.001]
  • [Cites] Pediatr Blood Cancer. 2004 Mar;42(3):261-7 [14752864.001]
  • [Cites] Med Pediatr Oncol. 1995 Jul;25(1):38-44 [7753001.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7621-31 [16234523.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):152-61 [11554387.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2187-91 [12775745.001]
  • [Cites] Cancer. 2000 May 1;88(9):2189-93 [10813733.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 May;64(5):391-7 [15892296.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):217-23 [16941074.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):984-93 [14970185.001]
  • (PMID = 18415046.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. McGregor LM, Spunt SL, Santana VM, Stewart CF, Ward DA, Watkins A, Laningham FH, Ivy P, Furman WL, Fouladi M: Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors. Cancer; 2009 Feb 1;115(3):655-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Responses were observed in patients with medulloblastoma (1 complete response) and pineoblastoma (1 partial response); 3 others with atypical teratoid rhabdoid tumor, ependymoma, and soft tissue sarcoma had prolonged disease stabilization.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • [Cites] Nephrol Dial Transplant. 1999 Jun;14(6):1441-4 [10383005.001]
  • [Cites] Neuro Oncol. 2000 Oct;2(4):213-20 [11265230.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2291-7 [17019740.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2274-80 [17538173.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Jun;29(6):355-60 [17551394.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):4028-9 [17664456.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6359-68 [17975148.001]
  • [Cites] Laryngoscope. 1999 Nov;109(11):1806-14 [10569412.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1193-202 [10715288.001]
  • [Cites] J Neurooncol. 1999;45(1):47-54 [10728909.001]
  • [Cites] Eur J Pharmacol. 2000 Oct 6;406(1):25-32 [11011028.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1592-601 [1403039.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):598-606 [8386751.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5663-8 [8242621.001]
  • [Cites] Cancer. 1994 Feb 15;73(4):1297-301 [8313334.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):931-6 [8164044.001]
  • [Cites] Med Pediatr Oncol. 1994;23(5):422-7 [8084309.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2390-7 [7964955.001]
  • [Cites] Semin Oncol. 1994 Oct;21(5 Suppl 12):61-4 [7992068.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):902-9 [7707117.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2247-54 [7666082.001]
  • [Cites] Cancer Res. 1995 Dec 15;55(24):6109-16 [8521401.001]
  • [Cites] Biochem Pharmacol. 1996 Dec 24;52(12):1855-65 [8951344.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Jan-Feb;19(1):62-7 [9065721.001]
  • [Cites] J Neurophysiol. 2001 May;85(5):2293-7 [11353042.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):229-36 [11885999.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):258-66 [11886003.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 15):21-33 [12422305.001]
  • [Cites] Mol Cancer Ther. 2002 Jan;1(3):227-35 [12467217.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):112-9 [12504667.001]
  • [Cites] Lancet Neurol. 2003 Jul;2(7):404-9 [12849118.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4055-61 [15217938.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Oct;26(10):649-55 [15454836.001]
  • [Cites] Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1459-73 [291480.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):459-63 [3546620.001]
  • [Cites] Cancer Treat Rep. 1987 May;71(5):525-7 [3567976.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):941-50 [3585448.001]
  • [Cites] Cancer Treat Rep. 1987 Jul-Aug;71(7-8):673-9 [3607781.001]
  • [Cites] J Clin Oncol. 1989 Jun;7(6):754-60 [2715805.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;25(4):299-303 [2295116.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):330-6 [2153766.001]
  • [Cites] Pediatr Hematol Oncol. 1987;4(4):329-36 [3152939.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;26(6):423-8 [2171796.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1990 Fall;12(3):297-300 [2173440.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2465-9 [2249186.001]
  • [Cites] Am J Nephrol. 1991;11(2):127-30 [1951473.001]
  • [Cites] Br J Cancer Suppl. 1992 Aug;18:S36-40 [1323992.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1425-8 [9108439.001]
  • [Cites] Invest New Drugs. 1997;15(2):109-14 [9220289.001]
  • [Cites] Med Pediatr Oncol. 1998 May;30(5):269-75 [9544222.001]
  • [Cites] Otolaryngol Head Neck Surg. 1998 May;118(5):584-8 [9591854.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2 Suppl 5):13-22 [9609104.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3579-85 [9721864.001]
  • [Cites] Eur J Cancer. 1999 Jan;35(1):86-90 [10211093.001]
  • [Cites] J Neurooncol. 1999 Feb;41(3):255-9 [10359145.001]
  • [Cites] Mol Pharmacol. 2000 Nov;58(5):920-7 [11040038.001]
  • [Cites] Pediatr Blood Cancer. 2005 Apr;44(4):363-9 [15586356.001]
  • (PMID = 19117350.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / P30 CA021765-31
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 6PLQ3CP4P3 / Etoposide
  • [Other-IDs] NLM/ NIHMS131860; NLM/ PMC2852396
  •  go-up   go-down


7. Blaney S, Berg SL, Pratt C, Weitman S, Sullivan J, Luchtman-Jones L, Bernstein M: A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res; 2001 Jan;7(1):32-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An MTD was defined in heavily pretreated and less-heavily pretreated (i.e., two prior chemotherapy regimens, no prior bone marrow transplantation, and no radiation to the spine, skull, ribs, or pelvic bones) patients.
  • Stable disease (4-20 cycles) was observed in seven patients with a variety of malignancies including neuroblastoma, pineoblastoma, glioblastoma, brainstem glioma, osteosarcoma, hepatoblastoma, and a central nervous system rhabdoid tumor.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Enzyme Inhibitors / therapeutic use. Neoplasms / drug therapy. Topoisomerase I Inhibitors
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Hematologic Tests. Humans. Infant. Infusions, Intravenous. Male. Toxicity Tests. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205914.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / MO1RR00188; United States / NCI NIH HHS / CA / U01CA57745
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


8. Stoiber EM, Schaible B, Herfarth K, Schulz-Ertner D, Huber PE, Debus J, Oertel S: Long term outcome of adolescent and adult patients with pineal parenchymal tumors treated with fractionated radiotherapy between 1982 and 2003--a single institution's experience. Radiat Oncol; 2010;5:122
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term outcome of adolescent and adult patients with pineal parenchymal tumors treated with fractionated radiotherapy between 1982 and 2003--a single institution's experience.
  • BACKGROUND: To evaluate the effectivity of fractionated radiotherapy in adolescent and adult patients with pineal parenchymal tumors (PPT).
  • 4 patients had a pineocytoma (PC), one a PPT with intermediate differentiation (PPTID) and 9 patients a pineoblastoma (PB), 2 of which were recurrences.
  • All patients underwent radiotherapy on the primary tumor site with a median total dose of 54 Gy.
  • In 9 patients with primary PB treatment included whole brain irradiation (3 patients) or irradiation of the craniospinal axis (6 patients) with a median total dose of 35 Gy.
  • Among 5 PB patients treated with radiotherapy without chemotherapy, 3 developed local or spinal tumor recurrence.
  • Diagnosis and treatment of patients with more aggressive variants of PPTIDs as well as treatment of PB needs to be further improved, since local and spinal failure even despite craniospinal irradiation (CSI) is common.
  • As PPT are very rare tumors, treatment within multi-institutional trials remains necessary.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Pineal Gland / pathology. Pinealoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiation Injuries / epidemiology. Radiotherapy / adverse effects. Radiotherapy / methods. Recurrence. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stereotact Funct Neurosurg. 1996;66 Suppl 1:164-73 [9032858.001]
  • [Cites] Childs Nerv Syst. 1998 Oct;14(10):564-9 [9840380.001]
  • [Cites] Acta Neurochir (Wien). 2006 Jan;148(1):5-11; discussion 11 [16172830.001]
  • [Cites] J Clin Neurosci. 2006 Nov;13(9):965-8 [16904896.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurooncol. 2008 Aug;89(1):89-95 [18415046.001]
  • [Cites] Neuro Oncol. 2009 Feb;11(1):33-40 [18796696.001]
  • [Cites] Prog Neurol Surg. 2009;23:44-58 [19329860.001]
  • [Cites] Prog Neurol Surg. 2009;23:106-18 [19329865.001]
  • [Cites] Radiother Oncol. 2009 Jul;92(1):83-8 [19328574.001]
  • [Cites] J Neurooncol. 2009 Sep;94(3):351-8 [19373436.001]
  • [Cites] Brain Pathol. 2000 Jan;10(1):49-60 [10668895.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):959-68 [10705018.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):141-4 [11083078.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):44-55; discussion 55-6 [12182434.001]
  • [Cites] Neurosurgery. 2002 Oct;51(4):880-9 [12234394.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2187-91 [12775745.001]
  • [Cites] Pediatr Blood Cancer. 2004 Mar;42(3):261-7 [14752864.001]
  • [Cites] Clin Neurosurg. 1985;32:384-96 [3905146.001]
  • [Cites] Cancer. 1989 Jan 15;63(2):302-4 [2910435.001]
  • [Cites] Neurosurgery. 1990 Oct;27(4):612-8; discussion 618-9 [2234367.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):870-80 [8334641.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1377-83 [7751882.001]
  • (PMID = 21184689.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3019157
  •  go-up   go-down


9. Hinkes BG, von Hoff K, Deinlein F, Warmuth-Metz M, Soerensen N, Timmermann B, Mittler U, Urban C, Bode U, Pietsch T, Schlegel PG, Kortmann RD, Kuehl J, Rutkowski S: Childhood pineoblastoma: experiences from the prospective multicenter trials HIT-SKK87, HIT-SKK92 and HIT91. J Neurooncol; 2007 Jan;81(2):217-23
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood pineoblastoma: experiences from the prospective multicenter trials HIT-SKK87, HIT-SKK92 and HIT91.
  • OBJECTIVE: To analyze the outcome of children with pineoblastoma (PB), treated within the prospective multicenter trials HIT-SKK87, HIT-SKK92 and HIT91 of German-speaking countries.
  • Five children younger than 3 years of age received chemotherapy after surgery until eligible for radiotherapy (HIT-SKK87 and HIT-SKK92).
  • Five of six children older than 3 years were treated after surgery with immediate chemotherapy and craniospinal irradiation, and one child received maintenance chemotherapy after postoperative radiotherapy (HIT91).
  • Five of these six HIT91 patients responded to postoperative chemotherapy and radiotherapy.
  • The only patient with tumor progression during initial chemotherapy achieved complete remission with radiotherapy and is alive.
  • Response to postoperative chemotherapy was lower than in the older age group, and only one of these children received radiotherapy.
  • CONCLUSIONS: Combined chemotherapy and radiotherapy were feasible and effective in the older age group, leading to prolonged remissions in five of six children.
  • Tumor biology may be more aggressive in younger children with PB, who presented more frequently with high-risk features at diagnosis and had poorer response rates to neoadjuvant postoperative chemotherapy.
  • More intensified treatment regimens may be needed for young children with PB.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Pineal Gland / pathology. Pinealoma / drug therapy. Pinealoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Pineoblastoma.
  • Genetic Alliance. consumer health - Pineoblastoma, childhood.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Childs Nerv Syst. 1999 Oct;15(10):586-91 [10550590.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1687-96 [7602359.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1377-83 [7751882.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1554-60 [16575007.001]
  • [Cites] Radiother Oncol. 2005 Dec;77(3):278-85 [16300848.001]
  • [Cites] Neurosurg Focus. 2005 Nov 15;19(5):E3 [16398467.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):433-7 [10666372.001]
  • [Cites] Klin Padiatr. 1998 Jul-Aug;210(4):227-33 [9743957.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):842-9 [11821469.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):842-5 [9041183.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jan;30(1):38-47 [11107174.001]
  • [Cites] Pediatr Blood Cancer. 2004 Mar;42(3):261-7 [14752864.001]
  • [Cites] Med Pediatr Oncol. 1995 Jul;25(1):38-44 [7753001.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7621-31 [16234523.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Aug;97(1):25-31 [9242214.001]
  • [Cites] J Neurooncol. 1996 Jul;29(1):55-68 [8817416.001]
  • [Cites] Neuron. 1999 Jan;22(1):103-14 [10027293.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):269-79 [10661332.001]
  • [Cites] J Neurosurg. 1994 Nov;81(5):690-8 [7931615.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1607-15 [8040673.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):978-86 [15758008.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1155-61 [8985038.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 15;28(2):431-8 [8276658.001]
  • [Cites] Cancer. 2000 May 1;88(9):2189-93 [10813733.001]
  • (PMID = 16941074.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. DeBoer R, Batjer H, Marymont M, Goldman S, Walker M, Gottardi-Littell N, Raizer J: Response of an adult patient with pineoblastoma to vorinostat and retinoic acid. J Neurooncol; 2009 Nov;95(2):289-292
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of an adult patient with pineoblastoma to vorinostat and retinoic acid.
  • We report the case of an adult patient with pineoblastoma (PBL) who had a complete radiographic response following treatment with vorinostat and retinoic acid.
  • This regimen was used to treat bulky residual tumor that persisted despite radiation therapy (RT) and two cycles of cytotoxic chemotherapy.
  • Vorinostat and retinoic acid were chosen as an alternative to cytotoxic chemotherapy, which our patient was unable to tolerate, based on preclinical data suggesting efficacy of this combination.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Pineal Gland. Pinealoma / drug therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Hydroxamic Acids / administration & dosage. Male. Prognosis. Radiotherapy Dosage. Treatment Outcome. Tretinoin / administration & dosage

  • Genetic Alliance. consumer health - Pineoblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Vorinostat .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2002 Jul;51(1):44-55; discussion 55-6 [12182434.001]
  • [Cites] Oncol Rep. 2006 Nov;16(5):1047-52 [17016591.001]
  • [Cites] Neurosurgery. 1995 Sep;37(3):383-90; discussion 390-1 [7501100.001]
  • [Cites] Oncogene. 2007 Feb 26;26(9):1351-6 [17322921.001]
  • [Cites] Int J Oncol. 2006 Mar;28(3):755-66 [16465382.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):259-70 [16645722.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2187-91 [12775745.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5541-52 [17694093.001]
  • [Cites] J Neurooncol. 2008 Apr;87(2):133-41 [18060600.001]
  • (PMID = 19506816.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydroxamic Acids; 5688UTC01R / Tretinoin; 58IFB293JI / vorinostat
  •  go-up   go-down


11. Tate MC, Banerjee A, Vandenberg SR, Tihan T, Chi JH, Ames CP, Parsa AT: Post-radiation reactive changes in a single vertebral body mimicking metastatic pineoblastoma. J Neurosurg Pediatr; 2009 Nov;4(5):479-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-radiation reactive changes in a single vertebral body mimicking metastatic pineoblastoma.
  • This 18-year-old woman presented with headache and diplopia over several months and was found to have an enhancing pineal tumor with resultant obstructive hydrocephalus.
  • Following standard preoperative diagnostic tests, including spinal axis imaging, the patient was taken to the operating room for an endoscopic third ventriculostomy to relieve hydrocephalus and then subsequently underwent a craniotomy for gross-total resection of the pineal mass.
  • The patient was discharged after an uneventful hospital course and received standard adjuvant cranial-spinal radiation and chemotherapy as an outpatient.
  • Follow-up imaging 1 year after surgery demonstrated a metabolically active, lytic lesion in the C-3 vertebral body and new lung lesions suggesting a metastatic pineoblastoma.
  • The patient underwent a C-3 anterior corpectomy and reconstruction without complication as aggressive therapy for presumed metastatic disease.
  • Final pathological results from the vertebral lesion were consistent with radiation-induced reactive changes, not metastatic pineoblastoma as originally suspected.
  • To the authors' knowledge this is the first reported case of reactive changes mimicking metastasis in a single vertebral body following standard therapy for resected primary pineoblastoma.
  • [MeSH-major] Brain Neoplasms / pathology. Pineal Gland / pathology. Pinealoma / pathology. Radiotherapy / adverse effects. Spine / pathology. Spine / radiation effects
  • [MeSH-minor] Adolescent. Craniotomy. Diplopia / etiology. Female. Humans. Hydrocephalus / complications. Magnetic Resonance Imaging. Neurosurgical Procedures. Tomography, X-Ray Computed. Ventriculostomy

  • Genetic Alliance. consumer health - Pineoblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19877784.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Constantine C, Miller DC, Gardner S, Balmaceda C, Finlay J: Osseous metastasis of pineoblastoma: a case report and review of the literature. J Neurooncol; 2005 Aug;74(1):53-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osseous metastasis of pineoblastoma: a case report and review of the literature.
  • PURPOSE: To review the literature on the occurrence of osseous metastases in recurrent pineoblastoma, and to report upon the feasibility and efficacy of treatment using intensive conventional chemotherapy to achieve a remission, followed by consolidation with marrow ablative chemotherapy and autologous hemopoietic stem cell rescue.
  • PATIENT AND METHODS: An adult with isolated extraneural, osseous and bone marrow metastases from a pineoblastoma, received conventional cyclical chemotherapy, followed by consolidation with marrow ablative chemotherapy (thiotepa, carboplatin and temozolomide) and autologous hemopoietic stem cell rescue.
  • RESULTS: A complete radiographic and histopathologic response was achieved after almost one year of conventional chemotherapy that was tolerated without significant sequelae.
  • Following successful harvesting of peripheral blood stem cells, the patient underwent myeloablative chemotherapy with autologous stem cell rescue, without difficulty in hemopoietic reconstitution and without serious or permanent side effects.
  • CONCLUSIONS: Osseous metastases from pineoblastoma are an extremely rare occurrence.
  • We conclude that conventional chemotherapy can achieve a complete response, and subsequent consolidation with marrow ablative chemotherapy and autologous hemopoietic stem cell rescue is feasible and well tolerated.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Bone Neoplasms / secondary. Brain Neoplasms / pathology. Pineal Gland / pathology. Pinealoma / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Diagnosis, Differential. Female. Germinoma / pathology. Hematopoietic Stem Cell Transplantation. Humans. Magnetic Resonance Imaging. Treatment Outcome

  • Genetic Alliance. consumer health - Pineoblastoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2001 Jul;125(7):939-43 [11419982.001]
  • [Cites] Can J Neurol Sci. 1987 Nov;14(4):586-92 [3500769.001]
  • [Cites] J Pathol. 1974 Sep;114(1):9-12 [4548088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):959-68 [10705018.001]
  • [Cites] J Neurosurg. 1990 Aug;73(2):287-90 [2195142.001]
  • [Cites] Clin Orthop Relat Res. 1989 Oct;(247):256-60 [2676297.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):107-14 [11716064.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):141-4 [11083078.001]
  • [Cites] Rinsho Hoshasen. 1971 Jul;16(7):564-75 [5208854.001]
  • [Cites] Med Pediatr Oncol. 1994;22(6):417-20 [8152405.001]
  • (PMID = 16078108.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Plowman PN, Pizer B, Kingston JE: Pineal parenchymal tumours: II. On the aggressive behaviour of pineoblastoma in patients with an inherited mutation of the RB1 gene. Clin Oncol (R Coll Radiol); 2004 Jun;16(4):244-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pineal parenchymal tumours: II. On the aggressive behaviour of pineoblastoma in patients with an inherited mutation of the RB1 gene.
  • This report relates to a retrospective analysis of two non-randomised cohorts of patients with pineoblastoma, with some differences in presenting features and treatment characteristics.
  • Eight children with familial retinoblastoma (non-metastatic at presentation) developed pineoblastoma and were treated by chemotherapy and radiotherapy.
  • The survival of these patients was compared with the survival of nine non-metastatic sporadic cases of pineoblastoma similarly staged and treated.
  • One out of eight children having the RB mutation in the genome survived compared with seven out of nine in the group with sporadic pineoblastoma (P = 0.002).
  • It is suggested that the inheritance of the mutated retinoblastoma gene is not only causal in the generation of this tumour type but, in a way that is yet to be defined, renders such tumours more aggressive or less responsive to therapy.
  • [MeSH-major] Brain Neoplasms / epidemiology. Pineal Gland. Pinealoma / epidemiology. Retinoblastoma Protein / genetics

  • Genetic Alliance. consumer health - Pineoblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15214647.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Retinoblastoma Protein
  •  go-up   go-down


14. Charafe-Jauffret E, Lehmann G, Fauchon F, Michiels JF, Paquis P, Maraninchi D, Hassoun J: Vertebral metastases from pineoblastoma. Arch Pathol Lab Med; 2001 Jul;125(7):939-43
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vertebral metastases from pineoblastoma.
  • In the first case in which the metastasis developed in the T8 corpus, the disease is presently under control after high-dose chemotherapy and autologous blood stem cell transplantation.
  • The second patient (sacral metastasis), despite aggressive adjuvant therapy, died 2 years after the last operation because of spinal seeding.
  • [MeSH-major] Brain Neoplasms / secondary. Pineal Gland. Pinealoma / pathology. Pinealoma / secondary. Spinal Neoplasms / pathology. Spinal Neoplasms / secondary
  • [MeSH-minor] Adolescent. Adult. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pineoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11419982.001).
  • [ISSN] 0003-9985
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Gururangan S, McLaughlin C, Quinn J, Rich J, Reardon D, Halperin EC, Herndon J 2nd, Fuchs H, George T, Provenzale J, Watral M, McLendon RE, Friedman A, Friedman HS, Kurtzberg J, Vredenbergh J, Martin PL: High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. J Clin Oncol; 2003 Jun 1;21(11):2187-91
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas.
  • PURPOSE: We evaluated the usefulness of a treatment regimen that included high-dose chemotherapy (HDC) with autologous stem-cell rescue (ASCR) in patients with newly diagnosed pineoblastoma (PBL).
  • PATIENTS AND METHODS: Twelve patients with PBL were initially treated with surgery and induction chemotherapy.
  • Five of 12 patients (42%) had a complete tumor resection at diagnosis.
  • Ten patients received radiotherapy at median doses of 36.0 and 59.4 Gy to the neuraxis and pineal region, respectively.
  • Nine patients are alive with no evidence of disease recurrence at a median of 62 months from diagnosis (range, 28 to 125 months), including three patients with metastatic disease and two infants who did not receive any radiotherapy.
  • Three patients have died of progressive disease at 19, 32, and 37 months from diagnosis, respectively.
  • CONCLUSION: The use of HDC in addition to radiotherapy seems to be an effective treatment for patients with newly diagnosed pineoblastoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Pineal Gland. Pinealoma / drug therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Busulfan / administration & dosage. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Humans. Infant. Male. Melphalan / administration & dosage. Middle Aged. North Carolina / epidemiology. Survival Rate. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12775745.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan; Q41OR9510P / Melphalan
  •  go-up   go-down


16. Jackson AS, Plowman PN: Pineal parenchymal tumours: I. Pineocytoma: a tumour responsive to platinum-based chemotherapy. Clin Oncol (R Coll Radiol); 2004 Jun;16(4):238-43
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pineal parenchymal tumours: I. Pineocytoma: a tumour responsive to platinum-based chemotherapy.
  • Pineocytoma and pineoblastoma are now recognised as a spectrum of the same disease.
  • Three cases of pineocytoma (grade I-II) are presented, in which platinum-based chemotherapy was used with some success, either as part of primary therapy or at the time of relapse.
  • With the recent reclassification of pineal parenchymal tumours into a grade I-IV continuum, the place of chemotherapy, previously only well-established in pineoblastoma, is discussed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / diagnosis. Pineal Gland. Pinealoma / diagnosis. Spinal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Diagnosis, Differential. Etoposide / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Pineocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15214646.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


17. Broniscer A, Nicolaides TP, Dunkel IJ, Gardner SL, Johnson J Jr, Allen JC, Sposto R, Finlay JL: High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumors. Pediatr Blood Cancer; 2004 Mar;42(3):261-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumors.
  • BACKGROUND: Recurrent non-cerebellar primitive neuroectodermal tumors (PNETs) carry a dismal prognosis when treated with conventional chemotherapy alone.
  • XSWe tested the efficacy of high-dose chemotherapy (HDC) followed by autologous stem-cell rescue (ASCR) in this setting.
  • PROCEDURE: Eligibility mandated either minimal residual disease or evidence of chemosensitivity before HDC.
  • RESULTS: Among 17 patients treated in this study, there were eight pineoblastoma(s) (pineo), seven cortical PNETs, and two arising elsewhere.
  • Two patients received HDC as the sole therapy for recurrence; additionally, eight underwent surgical debulking before HDC, and nine received irradiation, including six after HDC.
  • Surgical debulking before, and irradiation after HDC play an important role in treatment success.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Neuroectodermal Tumors / therapy. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Clinical Trials as Topic. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Infant. Male. Multicenter Studies as Topic. Recurrence. Retrospective Studies. Transplantation Conditioning / adverse effects. Transplantation Conditioning / methods. Transplantation, Autologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 14752864.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Rosenfeld A, Kletzel M, Duerst R, Jacobsohn D, Haut P, Weinstein J, Rademaker A, Schaefer C, Evans L, Fouts M, Goldman S: A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors. J Neurooncol; 2010 Apr;97(2):247-55
Hazardous Substances Data Bank. THIO-TEPA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors.
  • We studied tandem high dose chemotherapy (HDC) with hematopoietic progenitor stem cell rescues (HPCR) as potentially curative therapy.
  • Diagnoses were medulloblastoma (n = 9), germ cell tumor (n = 4), high grade astrocytoma (n = 2), supratentorial PNET (n = 1), pineoblastoma (n = 2), or papillary meningioma (n = 1).
  • Toxicity was significant with six treatment related deaths including four with veno-occlusive disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / therapy. Hematopoietic Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Carboplatin / administration & dosage. Carboplatin / adverse effects. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Thiotepa / administration & dosage. Thiotepa / adverse effects. Transplantation Conditioning

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):553-9 [9324343.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2891-6 [16782928.001]
  • [Cites] J Neurooncol. 2008 Feb;86(3):337-47 [17906911.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):33-8 [15719272.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1814-23 [9164190.001]
  • [Cites] Bone Marrow Transplant. 2000 Jul;26(2):153-60 [10918425.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1934-43 [15143087.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):382-8 [8636747.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2495-503 [8823328.001]
  • [Cites] J Neurooncol. 1999 Aug;44(1):77-83 [10582673.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2486-93 [9667268.001]
  • [Cites] Pediatr Hematol Oncol. 2004 Oct-Nov;21(7):635-45 [15626020.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):222-8 [9440746.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1226-30 [16622453.001]
  • [Cites] Bone Marrow Transplant. 1998 Oct;22(7):661-7 [9818693.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2284-92 [11980999.001]
  • (PMID = 19768658.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; 905Z5W3GKH / Thiotepa; BG3F62OND5 / Carboplatin; Q41OR9510P / Melphalan
  •  go-up   go-down


19. Dhall G, Khatua S, Finlay JL: Pineal region tumors in children. Curr Opin Neurol; 2010 Dec;23(6):576-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pineal region tumors in children.
  • PURPOSE OF REVIEW: Pineal tumors are rare in children, with pineoblastoma and germ cell tumors (GCTs) being the most common.
  • Here we discuss recent advances in treatment and controversies in the management of these tumors.
  • RECENT FINDINGS: There is significant heterogeneity in the clinical behavior of pineoblastoma in children.
  • We will discuss differences in outcome of children with pineoblastoma who are less than and greater than 3 years of age, and between pineoblastoma and nonpineal supratentorial primitive neuro-ectodermal tumors when treated with multiple different strategies.
  • Significant controversies exist in the treatment of GCTs as well, including the levels of tumor markers in the blood and cerebrospinal fluid that are required to establish without biopsy the diagnosis of a GCT, the role of surgery in GCTs and the optimal treatment for germinomas as well as mixed malignant GCTs.
  • SUMMARY: Although pineoblastoma in infants and very young children still remains a therapeutic challenge, significant progress has been made in the treatment of pineal GCTs with treatment strategies using a combination of chemotherapy and reduced dose and volume irradiation, resulting in increased survival rates and reduced long-term morbidity.
  • [MeSH-major] Antineoplastic Protocols / standards. Neoplasms, Germ Cell and Embryonal / therapy. Pinealoma / diagnosis. Pinealoma / therapy
  • [MeSH-minor] Age Factors. Antineoplastic Combined Chemotherapy Protocols / standards. Biomarkers, Tumor / blood. Child. Child, Preschool. Diagnosis, Differential. Humans. Infant. Survival Rate / trends. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042218.001).
  • [ISSN] 1473-6551
  • [Journal-full-title] Current opinion in neurology
  • [ISO-abbreviation] Curr. Opin. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


20. Reyns N, Hayashi M, Chinot O, Manera L, Péragut JC, Blond S, Régis J: The role of Gamma Knife radiosurgery in the treatment of pineal parenchymal tumours. Acta Neurochir (Wien); 2006 Jan;148(1):5-11; discussion 11
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of Gamma Knife radiosurgery in the treatment of pineal parenchymal tumours.
  • OBJECT: The aim of this study was to document the possible role of Gamma Knife radiosurgery, suitable for the treatment of deep and well limited tumors, in the management of pineal parenchymal tumors (PPT).
  • Radiosurgery was performed alone in 6 cases, after partial microsurgical resection in 3 cases, in association with chemotherapy in 3 cases and following conventional fractionated radiotherapy in 1 case.
  • The marginal dose to these tumors ranged from 11 to 20 Gy (mean 15 Gy).
  • RESULTS: With a mean follow-up of 34 months (range 6 to 88), all tumors responded to treatment and disappeared or ceased growing.
  • Two patients with pineoblastoma had tumor size progression out of the initial target requiring several radiosurgery procedures.
  • Two patients with pineoblastoma died because of carcinomatous meningitis or tumor size progression.
  • CONCLUSION: This study confirms that radiosurgery can be an effective and safe primary treatment modality for patients with pineocytomas.
  • It should have a role in multimodality therapy which includes microsurgical resection, fractionated radiotherapy and chemotherapy for the management of malignant pineal tumors.
  • [MeSH-major] Brain Neoplasms / surgery. Pineal Gland. Pinealoma / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172830.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


21. Fischer B, Palkovic S, Wassmann H: Treatment strategy of pineal tumors in consideration of their pathomorphology. Bratisl Lek Listy; 2004;105(3):95-100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment strategy of pineal tumors in consideration of their pathomorphology.
  • BACKGROUND: Tumors of the pineal gland are rare pathology.
  • This paper reports on therapeutical considerations of histologically heterogeneous pineal tumors in a group of 15 patients and is presenting a special case of neuroaxial seeding.
  • METHODS: Surgery and/or additional therapeutic procedures were performed in 13 of our 15 patients ("youngster" and "adults") in respect of pathomorphology.
  • Details are reported concerning a 52-year-old man suffering from pineocytoma (WHO grade II), who underwent different kinds of therapy within 10 years follow-up.
  • RESULTS: In the six "youngster" the histological assessment revealed two teratomas, one mixed pineocytoma/pineoblastoma, one astrocytoma and one epidermoid cyst.
  • Additional radio-/chemotherapy was used in a case of teratoma and pineocytoma/pineoblastoma.
  • From five successfully surgically treated "adults" (germinoma, pineoblastoma, pineocytoma, two cystic formations) in two of them (germinoma, pineoblastoma) additional radiotherapy was needed, another two patients (cystic formations) were healed after stereotactic puncture.
  • CONCLUSION: Precise histopathological assessment of pineal tumors is essential to guide optimal modern therapy modalities in order to assure a local tumor control. (Fig. 3, Ref. 18.).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15253526.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


22. Kellie SJ, Wong CK, Pozza LD, Waters KD, Lockwood L, Mauger DC, White L: Activity of postoperative carboplatin, etoposide, and high-dose methotrexate in pediatric CNS embryonal tumors: results of a phase II study in newly diagnosed children. Med Pediatr Oncol; 2002 Sep;39(3):168-74
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Chemotherapy is used as an alternative to irradiation or to minimize the irradiation exposure among infants with medulloblastoma or other CNS embryonal tumors.
  • Adjuvant chemotherapy is commonly used in older children with high-risk medulloblastoma to improve survival or to allow a reduction in the craniospinal irradiation dose in standard-risk patients.
  • However, optimal multimodality therapy, including the precise role of chemotherapy, has not been defined for these groups of patients.
  • PROCEDURE: Twenty-eight children, aged from 0.3 to 15.9 years (median, 6.2 years) with post-operative measurable residual CNS embryonal tumors were enrolled, comprising medulloblastoma (n = 19), supratentorial PNET (n = 7), and pineoblastoma (n = 2).
  • Post-operative chemotherapy comprised carboplatin 350 mg/m(2) and etoposide 100 mg/m(2) on Days 1 & 2, and methotrexate 8 g/m(2) on Day 3, repeated at 21-28-day intervals for a total of four courses.
  • Therapy following completion of the initial Phase II study was influenced by patient age and investigator preference.
  • RESULTS: The combined complete response rate (CR, 7/19) and partial response rate (PR, 7/19) was 74% in patients with medulloblastoma, 89% for patients with PNET/pineoblastoma (CR, 2/9 and PR, 6/9), and for all patients it was 79%.
  • Patients aged < 3 years at diagnosis had a combined PR and CR rate of 71% compared to 81% in patients aged > 3 years.
  • Treatment was well tolerated although myelosuppression and thrombocytopenia were common.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Medulloblastoma / drug therapy. Neoplasms, Germ Cell and Embryonal / drug therapy
  • [MeSH-minor] Adolescent. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Infant. Male. Methotrexate / administration & dosage. Prognosis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12210445.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


23. Tamaki N, Yin D: Therapeutic strategies and surgical results for pineal region tumours. J Clin Neurosci; 2000 Mar;7(2):125-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic strategies and surgical results for pineal region tumours.
  • Until recently, surgery for pineal region tumours has met with poor results.
  • Over 26 years we treated 36 patients including: 24 with germinoma; four, teratoma; three, pineal cyst; and one each, embryonal carcinoma, choriocarcinoma, pineocytoma, pineoblastoma and metastasis.
  • All 24 germinomas responded to radiotherapy, as did one case each for teratoma, pineoblastoma, and choriocarcinoma.
  • Current operative techniques allow safe, effective removal of pineal region tumours.
  • [MeSH-major] Brain Neoplasms / therapy. Pineal Gland. Pinealoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Drug Therapy. Female. Gonadotropins / cerebrospinal fluid. Humans. Infant. Male. Microsurgery / methods. Middle Aged. Neurosurgical Procedures / methods. Radiotherapy. Retrospective Studies. Treatment Outcome. alpha-Fetoproteins / cerebrospinal fluid

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Harcourt Publishers Ltd.
  • (PMID = 10844797.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Gonadotropins; 0 / alpha-Fetoproteins
  •  go-up   go-down


24. Burzynski SR, Weaver RA, Janicki T, Szymkowski B, Jurida G, Khan M, Dolgopolov V: Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1. Integr Cancer Ther; 2005 Jun;4(2):168-77
Hazardous Substances Data Bank. Glutamine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primitive neuroectodermal tumors (PNETs) are usually successfully treated with craniospinal radiation and chemotherapy; however, difficulties with standard treatment can be encountered in very young children, in adult patients at high risk of complication from standard treatment, and in patients with recurrent tumors.
  • Medulloblastoma was diagnosed in 8 patients, pineoblastoma in 3 patients, and other PNET in 2 patients.
  • Previous treatments included surgery in 12 patients (1 had biopsy only, suboccipital craniotomy), chemotherapy in 6 patients, and radiation therapy in 6 patients.
  • Six patients had not received prior chemotherapy or radiation.
  • The treatment consisted of intravenous infusions of 2 formulations of ANP, A10 and AS2-1, and was administered for an average of 20 months.
  • Six patients (46%) survived more than 5 years from initiation of ANP; 5 were not treated earlier with radiation therapy or chemotherapy.
  • The percentage of patients' response is lower than for standard treatment of favorable PNET, but long-term survival in poor-risk cases and reduced toxicity makes ANP promising for very young children, patients at high risk of complication of standard therapy, and patients with recurrent tumors.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Benzeneacetamides / administration & dosage. Brain Neoplasms / drug therapy. Glutamine / analogs & derivatives. Neuroectodermal Tumors, Primitive / drug therapy. Phenylacetates / administration & dosage. Piperidones / administration & dosage
  • [MeSH-minor] Child, Preschool. Disease Progression. Drug Combinations. Drug Therapy, Combination. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / prevention & control. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15911929.001).
  • [ISSN] 1534-7354
  • [Journal-full-title] Integrative cancer therapies
  • [ISO-abbreviation] Integr Cancer Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzeneacetamides; 0 / Drug Combinations; 0 / Phenylacetates; 0 / Piperidones; 0RH81L854J / Glutamine; 104624-98-8 / antineoplaston AS 2-1; 91531-30-5 / antineoplaston A10
  •  go-up   go-down


25. Kanamori M, Kumabe T, Tominaga T: Is histological diagnosis necessary to start treatment for germ cell tumours in the pineal region? J Clin Neurosci; 2008 Sep;15(9):978-87
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is histological diagnosis necessary to start treatment for germ cell tumours in the pineal region?
  • The significance of histological diagnosis was retrospectively investigated in the treatment of 79 consecutive patients with pineal region tumours.
  • The single exception was pineoblastoma.
  • Forty-one patients were treated under a clinical diagnosis of pineal germ cell tumour using neoadjuvant chemotherapy and radiation therapy without histological verification.
  • Most cases of pineal germ cell tumour could be identified on the basis of clinical findings only, and could be treated appropriately using neoadjuvant chemotherapy and radiation therapy without histological diagnosis.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / therapy. Pineal Gland / pathology. Pinealoma / diagnosis. Pinealoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Protocols / standards. Biomarkers, Tumor / analysis. Child. Child, Preschool. Decision Support Techniques. Female. Humans. Infant. Male. Middle Aged. Neurosurgical Procedures. Predictive Value of Tests. Radiotherapy / methods. Retrospective Studies. Teratoma / diagnosis. Teratoma / metabolism. Teratoma / therapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18617412.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


26. Pitskhelauri DI, Konovalov AN, Azizian VN, Kornienko VN, Korshunov AG, Melikian AG, Loshakov VA, Serova NK: [Iatrogenic metastasis of pineal tumors]. Zh Vopr Neirokhir Im N N Burdenko; 2004 Oct-Dec;(4):28-33; discussion 33-4
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Iatrogenic metastasis of pineal tumors].
  • [Transliterated title] Iatrogennoe metastazirovanie opukholeĭ pineal'noĭ oblasti.
  • Malignant pineal tumors (PT) tend to metastasize.
  • The sources of metastases were pineoblastoma (n = 1), malignant teratoma (n = 1), germinoma (n = 1), and malignant germ-cell tumor of unknown genesis (n = 1).
  • To prevent this complication due to high-grade PT, such as malignant germ-cell tumors and pineoblastomas, radiation of the whole brain, besides the sites of a tumor should be performed and, in some cases, in combination with chemotherapy.
  • [MeSH-minor] Adolescent. Child, Preschool. Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / secondary. Humans. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local. Pineal Gland. Postoperative Complications / pathology. Teratoma / pathology. Teratoma / secondary. Teratoma / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15724549.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia
  •  go-up   go-down


27. Antoneli CB, Ribeiro Kde C, Sakamoto LH, Chojniak MM, Novaes PE, Arias VE: Trilateral retinoblastoma. Pediatr Blood Cancer; 2007 Mar;48(3):306-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article reports four cases of TRB and discusses the role of neuroimaging screening for early detection.
  • PROCEDURE: From January 1986 to December 2003, 470 children with Rb were admitted to the Pediatrics and Ophthalmology Departments, A C Camargo Hospital, São Paulo, Brazil.
  • RESULTS: There were four patients with pineoblastoma, two of whom had a positive familial history.
  • The age at diagnosis of Rb was 4, 6, 10, and 24 months while the age of diagnosis of TRB was 10, 25, 57, and 72 months.
  • One patient presented TRB at initial diagnosis of Rb.
  • Three patients had bilateral disease and all of them had one eye enucleated, followed by chemotherapy and/or external beam radiation therapy (EBRT).
  • In spite of intensive treatment, all patients died with progressive disease within 7, 8, 12, and 12 months after diagnosis of TRB.
  • CONCLUSIONS: Early diagnosis as well as new therapeutic approaches are needed to achieve better results.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Cyclophosphamide / administration & dosage. Disease Progression. Etoposide / administration & dosage. Eye Enucleation. Fatal Outcome. Female. Humans. Idarubicin / administration & dosage. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Neoplastic Syndromes, Hereditary / genetics. Neoplastic Syndromes, Hereditary / pathology. Prognosis. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for trilateral retinoblastoma .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16572402.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ZRP63D75JW / Idarubicin
  • [Number-of-references] 27
  •  go-up   go-down


28. Lutterbach J, Fauchon F, Schild SE, Chang SM, Pagenstecher A, Volk B, Ostertag C, Momm F, Jouvet A: Malignant pineal parenchymal tumors in adult patients: patterns of care and prognostic factors. Neurosurgery; 2002 Jul;51(1):44-55; discussion 55-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pineal parenchymal tumors in adult patients: patterns of care and prognostic factors.
  • OBJECTIVE: The aim of our study was to analyze patterns of care and to identify prognostic factors in patients at least 18 years of age who received radiotherapy for malignant pineal parenchymal tumors.
  • Chemotherapy was administered to 34 patients.
  • The variables that significantly influenced overall survival were the extent of disease (localized versus disseminated; P = 0.0002), differentiation (pineal parenchymal tumor of intermediate differentiation versus pineoblastoma; P = 0.001), and residual disease (> or = 50% versus < 50% reduction in size; P < 0.0001).
  • Spinal control was more successful in patients with pineal parenchymal tumors of intermediate differentiation than it was in patients with pineoblastomas (P = 0.03).
  • Nine of 45 treatment failures occurred later than 5 years after treatment.
  • CONCLUSION: Stage, histological characteristics, and response are independent risk factors in adults with malignant pineal parenchymal tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Critical Pathways / statistics & numerical data. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pineal Gland / pathology. Pineal Gland / surgery. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12182434.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


29. Nomura K: Epidemiology of germ cell tumors in Asia of pineal region tumor. J Neurooncol; 2001 Sep;54(3):211-7
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of germ cell tumors in Asia of pineal region tumor.
  • A higher incidence of pineal region tumors in Asian countries compared to Western countries has been reported.
  • In the Brain Tumor Registry of Japan (BTRJ), there were 38,273 primary brain tumors except those of unknown histology (1123 cases) registered in the period between 1984 and 1993, in which 807 pineal region tumors with 104 unknown histology were registered in BTRJ.
  • Of these pineal region tumors, germ cell tumors had the highest frequency, 70.3%, followed by pineal parenchymal tumors, 12.0%; pineocytoma in 7.8% and pineoblastoma in 4.2%.
  • Limited to germ cell tumors, germinoma was 68.0%, then teratoma including malignant teratoma, had the second high frequency, 14.7% in pineal region.
  • While data reported by Allaire et al. and Edwards et al. revealed that the incidence of germinoma was 88.6%, 52.4% of germ cell tumors in pineal region in France and in USA, respectively.
  • Although number of cases is very small, it is suggested that the percentage of germinoma in germ cell tumors in the pineal region might be almost the same in Western countries as in Asian countries, and the occurrence of germ cell tumors in the pineal region was much higher than those in Asia.
  • Age and gender distribution of pineal region tumors indicated that germ cell tumors and pineocytoma showed a high incidence in males and in children.
  • Most of malignant pineal region tumors other than germinomas showed poor prognosis, but recent progress in surgical techniques and effective chemotherapy will improve the prognosis.
  • [MeSH-major] Brain Neoplasms / epidemiology. Germinoma / epidemiology. Pineal Gland

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1969 Feb;30(2):146-9 [5780883.001]
  • [Cites] Childs Nerv Syst. 1998 Jan-Feb;14(1-2):36-40 [9548339.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):133-7 [10413166.001]
  • [Cites] Clin Neurosurg. 1983;30:59-91 [6321079.001]
  • [Cites] Jpn J Clin Oncol. 1987 Mar;17(1):19-28 [3560463.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):446-55 [9046301.001]
  • [Cites] J Neurooncol. 1998 Nov;40(2):151-60 [9892097.001]
  • [Cites] Childs Nerv Syst. 1998 Jan-Feb;14(1-2):41-8 [9548340.001]
  • [Cites] J Neurosurg. 1988 May;68(5):689-97 [2451717.001]
  • (PMID = 11767288.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


30. Yurtseven T, Erşahin Y, Demirtaş E, Mutluer S: Neuroendoscopic biopsy for intraventricular tumors. Minim Invasive Neurosurg; 2003 Oct;46(5):293-9
MedlinePlus Health Information. consumer health - Biopsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Location of the tumors were as follows: pineal region in 7, hypothalamus and 3rd ventricle in 4, lateral ventricle in 4, thalamus in 2, and tectal in 1 patient.
  • Cerebrospinal fluid (CSF) was collected at the beginning of the procedure for cytological analysis and for pineal tumor markers.
  • Biopsy forceps were used to obtain tissue from the lesion.
  • The third ventriculostomy was performed in all patients with a pineal tumor, in addition to the tumor biopsy.
  • The pathological examinations revealed a low-grade astrocytoma in 6 patients, anaplastic astrocytoma in 3, germinoma in 3, pineocytoma in 1, pineoblastoma in 2, glioblastoma multiforme in 1 and granulomatous lesion in 1.
  • Subsequent mode of treatment such as radiation therapy, chemotherapy or radical surgery was determined on the basis of pathological diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14628246.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Gilheeney SW, Khakoo Y, Souweidane M, Wolden S, Boulad F, Dunkel IJ: Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system. Pediatr Blood Cancer; 2010 Apr;54(4):591-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present ten patients with recurrent or progressive central nervous system malignancies treated on a myeloablative regimen using these drugs.
  • METHODS: Treatment included: Thiotepa 300 mg/m(2) on days -8, -7, and -6; topotecan 2 mg/m(2) on days -8, -7, -6, -5, and -4; and carboplatin approximately 500 mg/m(2) (Calvert formula-area under the curve = 7) on days -5, -4, and -3.
  • Five had medulloblastoma (MB), four had high grade glioma (HGG), and one had trilateral retinoblastoma/pineoblastoma (tRB/PB).
  • Prior treatment for all patients included surgery and chemotherapy (1-7 regimens, median 2).
  • Three patients had residual disease at the time of transplant.
  • Four patients are event-free survivors at a median of 6 years (range 2.8-7.6 years) after treatment including 2/5 MB patients, 1/4 HGG patients, and the tRB/PB patient.
  • Four of the seven patients with no evidence of disease/minimal residual disease status at the time of stem cell rescue are long-term survivors versus 1/3 with measurable disease.
  • Diagnosis and extent of disease prior to stem cell rescue may have an impact on outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Carboplatin / administration & dosage. Carboplatin / adverse effects. Child. Child, Preschool. Combined Modality Therapy. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Neoplasm Recurrence, Local / drug therapy. Prognosis. Thiotepa / administration & dosage. Thiotepa / adverse effects. Topotecan / administration & dosage. Topotecan / adverse effects. Young Adult

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19998470.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan; 905Z5W3GKH / Thiotepa; BG3F62OND5 / Carboplatin
  •  go-up   go-down


32. Oi S, Shibata M, Tominaga J, Honda Y, Shinoda M, Takei F, Tsugane R, Matsuzawa K, Sato O: Efficacy of neuroendoscopic procedures in minimally invasive preferential management of pineal region tumors: a prospective study. J Neurosurg; 2000 Aug;93(2):245-53
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of neuroendoscopic procedures in minimally invasive preferential management of pineal region tumors: a prospective study.
  • OBJECT: This prospective study is based on a consecutive series of 20 patients with pineal region tumors who underwent minimally invasive preferential management.
  • The purpose of this report is to discuss the role of neuroendoscopic procedures in the management of pineal region tumors.
  • METHODS: If the tumor markers alpha-fetoprotein and human chorionic gonadotropin were not detected in serum and there was significant ventricular dilation visualized on neuroimages, neuroendoscopic surgery was first applied for tumor debulking with tissue diagnosis and gross morphological analysis of the tumor and the intraventricular structures, followed by third ventriculostomy.
  • For treatment of germinomas and pineoblastomas, if no tumor dissemination was confirmed by pre-, intra-, or postoperative findings, stereotactic radiotherapy or radiosurgery was performed after one course of chemotherapy with the ICE regimen (isofomid, cisplatin, and etoposide) and followed by two additional courses of chemotherapy.
  • For treatment of malignant germ cell tumors, after extensive surgery, adjuvant chemotherapy with the ICE regimen was performed in three courses in all cases.
  • For treatment of teratomatous and neuroectodermal tumors other than pineoblastomas, extensive surgical removal was performed.
  • As for adjuvant therapy, if the tumor was a low-grade glioma or if the patient was younger than 5 years of age, postoperative treatment did not include radiotherapy.
  • If the tumor was a malignant teratoma or high-grade glioma, conventional focal radiotherapy was performed, followed by chemotherapy with ICE for 1 year.
  • Neuroendoscopic biopsy with tumor debulking offered enough material for tissue diagnosis, including immunohistochemical analysis and, in one case, revealed evidence of tumor dissemination undetectable on neuroimaging.
  • Favorable therapeutic outcomes were obtained in all cases of germinoma and pineoblastoma, with follow-up periods ranging from 24 months to 6.5 years.
  • CONCLUSIONS: Our minimally invasive preferential regimen clarified the precise indication for neuroendoscopic procedures, and the majority of our patients with dilated ventricles and no evidence of tumor markers were treated satisfactorily with effective neuroendoscopic procedures as the initial procedure, avoiding unnecessary craniotomy and radiotherapy and promising excellent therapeutic outcomes.
  • The treatment for malignant pineal region tumors remains a subject for further study.
  • [MeSH-major] Brain Neoplasms / surgery. Endoscopy. Minimally Invasive Surgical Procedures. Pineal Gland / surgery. Pinealoma / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Child. Female. Glioma / pathology. Glioma / surgery. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiotherapy, Adjuvant. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10930010.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


33. Oliveira JP, Gazzola Lde P, Araújo Sde A: Severe cytomegalic pneumonitis associated with pulmonary aspergillosis in a child with immunosuppression due to chemotherapy for treating pineoblastoma. Rev Soc Bras Med Trop; 2009 Jan-Feb;42(1):86-7
MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe cytomegalic pneumonitis associated with pulmonary aspergillosis in a child with immunosuppression due to chemotherapy for treating pineoblastoma.
  • [MeSH-minor] Brain Neoplasms / drug therapy. Child. Female. Humans. Pineal Gland. Pinealoma / drug therapy. Severity of Illness Index

  • Genetic Alliance. consumer health - Pineoblastoma.
  • Genetic Alliance. consumer health - Aspergillosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287944.001).
  • [ISSN] 1678-9849
  • [Journal-full-title] Revista da Sociedade Brasileira de Medicina Tropical
  • [ISO-abbreviation] Rev. Soc. Bras. Med. Trop.
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


34. Nozza P, Casciana ML, Rossi A, Cama A, Milanaccio C, Raso A, Ravegnani M, Morreale G, Garrè ML: Post-chemotherapy maturation of a pineoblastoma. Acta Neuropathol; 2010 May;119(5):651-3
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-chemotherapy maturation of a pineoblastoma.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Pineal Gland / pathology. Pinealoma / drug therapy. Pinealoma / pathology
  • [MeSH-minor] Humans. Infant. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Pineoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20224924.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement